Robert Besthof - Mar 8, 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Interim CEO
Signature
/s/ Robert Besthof
Stock symbol
NRXP
Transactions as of
Mar 8, 2022
Transactions value $
$261,000
Form type
4
Date filed
3/10/2022, 03:04 PM
Previous filing
Nov 2, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Employee Stock Option Award $261K +100K +40.45% $2.61* 347K Mar 8, 2022 Common Stock 100K $2.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc.